Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT02017457
Other study ID # BHS-TC-10
Secondary ID
Status Completed
Phase Phase 2
First received
Last updated
Start date December 2013
Est. completion date November 2019

Study information

Verified date December 2019
Source University Hospital of Mont-Godinne
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The present project is a multicenter, phase II trial which aims at evaluating if the administration of azacytidine (Vidaza®) combined to donor lymphocyte infusion (DLI) could improve the response rate to DLI in the population of patients with relapsed acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) after allogeneic hematopoietic stem cell transplantation.


Description:

This is a prospective, multicenter, non-randomized phase II study. The aims at evaluating if the administration of azacytidine (Vidaza®) combined to donor lymphocyte infusion (DLI) could improve the response rate to DLI in the population of patients with relapsed acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) after allogeneic hematopoietic stem cell transplantation.

Because the investigators focus our interest on relapsed MDS and low marrow blast count relapsed AML, the investigators postulate that one cycle at higher doses of azacytidine given at 100 mg/m² during 5 days is enough to induce temporary disease control, as suggested by the predictive value of the immediate response rate after the first cycle described in the study of Czibere et al. Starting with cycle 2, the investigators propose to administer DLI along with azacytidine to optimise the immunomodulatory effect. Because these immunomodulatory effects have been described at low dose, the investigators postulate that 35 mg/m² given during 5 days is enough to harness a graft-versus-leukemia effect and induce durable remissions without exacerbating GvHD. DLI will be given every other cycle following an escalated-dose regimen.

The investigators have estimated a sample size of 50 patients to be recruited during 4 years with a 2-year follow-up and a 3-year long-term follow-up. The whole study will be completed within 9 years.


Recruitment information / eligibility

Status Completed
Enrollment 50
Est. completion date November 2019
Est. primary completion date November 2019
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria:

1. Patients:

- Age = 18 years

- Be able to understand and sign informed consent

- Fertile patients must use a reliable contraception method

2. Disease status at transplantation:

- AML in first or subsequent complete remission (< 5% marrow blasts)

- MDS with less than 10% marrow blasts at the time of transplantation

3. Transplantation:

- Allogeneic transplantation using a sibling or unrelated donor with matching in 10/10 alleles (HLA-A, B, C, DRB1, DQB1) or maximum of one allele or one antigen or 1 antigen + 1 allele or 1 antigen + 1 DQB1 antigen or 2 alleles mismatches.

- Myeloablative or reduced-intensity conditioning

- Second transplantation is allowed

- Donor is willing to donate lymphocytes

4. Clinical situation:

- Cytological relapse after allo-SCT defined as the recurrence of more than 5% blasts on bone marrow aspiration (AML) or evidence of MDS

- Immunophenotypic relapse defined as the recurrence of an abnormal phenotype on flow cytometry in bone marrow aspirate (only in case of a specific phenotype).

- Cytogenetic or molecular relapse defined as the persistence or recurrence of a cytogenetic abnormality or molecular marker in bone marrow aspiration or peripheral blood. WT1 expression is not considered as reliable marker for relapse in this protocol but FLT3-ITD, NPM1, CEBPA, or translocation-specific markers (such as MLL-PTD, AML-ETO, CBFB-MYH11) are.

5. Immunosuppressive therapy should have been stopped before inclusion.

Exclusion Criteria:

- More than 30% marrow blasts at the time of inclusion

- Extramedullary relapse including CNS involvement

- ECOG Performance status > 2

- Active acute grade II-IV GvHD at the time of inclusion

- Active chronic GvHD requiring systemic therapy at the time of inclusion

- Uncontrolled infection

- HIV positive

- Acute or chronic heart failure (NYHA class III or IV) or symptomatic ischemic heart disease or ejection fraction < 35% or uncontrolled arrhythmia

- Severe liver failure (total bilirubin > 3 mg/dL, SGPT > 4 X upper normal limit)

- Severe pulmonary failure (corrected DLCo < 35%)

- Terminal renal failure requiring dialysis

- Severe neurological or psychiatric disorders

- Concurrent investigational drug.

- Other treatment for relapse, except for hydroxyurea but it should be stopped before inclusion in the study.

- Female who is pregnant or breastfeeding

Study Design


Intervention

Biological:
Donor lymphocyte infusion
On day 1 of cycle 2, 4 and 6 of Azacytidine, patients will be infused with donor lymphocytes (ideally on day 1 but in case of organizational problems, DLI can be administered until day 5) . Patients with a sibling donor will receive: 5x10exp7 CD3+/kg on day 1 of cycle 2 5x10exp7 CD3+/kg on day 1 of cycle 4 10x10exp7 CD3+/kg on day 1 of cycle 6 Patients with an unrelated donor will receive: 1x10exp7 CD3+/kg on day 1 of cycle 2 5x10exp7 CD3+/kg on day 1 of cycle 4 10x10exp7 CD3+/kg on day 1 of cycle 6
Drug:
Azacytidine
Cycle 1: Subcutaneous administration of 100mg/m2/day for 5 days. Cycle 2: Subcutaneous administration of 35mg/m2/day for 5 days. Cycles will be administered every 28 days. All patients will receive at least 6 cycles of Azacytidine except if progression requests additional disease-related treatment such as hydroxyurea or other chemotherapeutic agents. In such cases, the patient will be excluded from the study and only disease status and survival status will be reported during the 3-year follow-up period. In case of complete remission after cycle 5, 2 additional cycles will be administered after achievement of complete remission. In case of stable disease or partial response, Azacytidine will be continued until progression. In case of disease progression after cycle 6, Azacytidine will be stopped.

Locations

Country Name City State
Belgium Ziekenhuis Netwerk Antwerpen Antwerpen
Belgium AZ Sint-Jan Brugge Brugge
Belgium Institut Jules Bordet Brussels
Belgium Universitair Ziekenhuis Antwerpen Edegem
Belgium Universitair Ziekenhuis Gent Gent
Belgium Hopital de Jolimont Haine-St-Paul
Belgium Universitair Ziekenhuis Brussel Jette
Belgium Universitair Ziekenhuis Leuven Leuven
Belgium CHU Liège Liège
Belgium Hartziekenhuis Roeselare Menen Roeselare
Belgium Cliniques Universitaires Saint-Luc Woluwe-Saint-Lambert
Belgium CHU Mont-Godinne Yvoir

Sponsors (3)

Lead Sponsor Collaborator
Carlos Graux, MD, PhD Belgian Hematological Society, Celgene Corporation

Country where clinical trial is conducted

Belgium, 

Outcome

Type Measure Description Time frame Safety issue
Other Immune reconstitution Immune reconstitution (hemoglobuline in g/dL) On day 1 of each cycle until cycle 6, then every 3 months for a year and at 1.5 and 2 years after cycle 6
Other Immune reconstitution Immune reconstitution (ANC, ALC, platelet in cells/µL) On day 1 of each cycle until cycle 6, then every 3 months for a year and at 1.5 and 2 years after cycle 6
Other Treg expansion Treg expansion On day 1 of each cycle until cycle 6, then every 3 months for a year and at 1.5 and 2 years after cycle 6
Primary Response rate To assess the response rate to DLI by the combination with azacytidine in the population of patients with relapsed AML and MDS after allo-SCT. Will be evaluated at day 24 of cycle 1, 3 and 5. Then every 3 months for a year after cycle 6 thereafter at 1.5 and 2 years after cycle 6
Secondary Disease-free survival Disease-free survival of patients 2 years after cycle 6
Secondary Overall survival Overall survival of patients 2 years after cycle 6
Secondary Evaluation of the treatment Toxicity Evaluate haematological and non-haematological toxicities and safety of the planned therapy. At the beginning of each cycle and at the discretion of the investigator until cycle 6, then monthly for 6 months, thereafter every 3 months for 1.5 years
Secondary Incidence and severity of GvHD Incidence and severity of GvHD At the beginning of each cycle and at the discretion of the investigator until cycle 6, then monthly for 6 months, thereafter every 3 months for 1.5 years
Secondary Incidence and severity of infections Incidence and severity of infections At the beginning of each cycle and at the discretion of the investigator until cycle 6, then monthly for 6 months, thereafter every 3 months for 1.5 years
See also
  Status Clinical Trial Phase
Completed NCT04022785 - PLX51107 and Azacitidine in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome Phase 1
Completed NCT01200355 - Posaconazole Versus Micafungin for Prophylaxis Against Invasive Fungal Infections During Neutropenia in Patients Undergoing Chemotherapy for Acute Myelogenous Leukemia, Acute Lymphocytic Leukemia or Myelodysplastic Syndrome Phase 4
Active, not recruiting NCT02530463 - Nivolumab and/or Ipilimumab With or Without Azacitidine in Treating Patients With Myelodysplastic Syndrome Phase 2
Completed NCT02057185 - Occupational Status and Hematological Disease
Completed NCT01682226 - Cord Blood With T-Cell Depleted Haplo-identical Peripheral Blood Stem Cell Transplantation for Hematological Malignancies Phase 2
Completed NCT02485535 - Selinexor in Treating Patients With Intermediate- and High-Risk Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome After Transplant Phase 1
Completed NCT03941769 - 2018-0674 - IL-7 for T-Cell Recovery Post Haplo and CB Transplant - Phase I/II Phase 1/Phase 2
Completed NCT00001637 - Immunosuppressive Preparation Followed by Blood Cell Transplant for the Treatment of Blood Cancers in Older Adults Phase 2
Recruiting NCT06195891 - Orca-T Following Chemotherapy and Total Marrow and Lymphoid Irradiation for the Treatment of Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia or Myelodysplastic Syndrome Phase 1
Active, not recruiting NCT04188678 - Resiliency in Older Adults Undergoing Bone Marrow Transplant N/A
Completed NCT00987480 - Hematopoietic Stem Cell Transplantation for the Treatment of Patients With Fanconi Anemia Lacking a Genotypically Identical Donor, Using a Chemotherapy Only Cytoreduction With Busulfan, Cyclophosphamide and Fludarabine Phase 2
Recruiting NCT02356159 - Study of Palifermin (Kepivance) in Persons Undergoing Unrelated Donor Allogeneic Hematopoietic Cell Transplantation Phase 1/Phase 2
Completed NCT04666025 - SARS-CoV-2 Donor-Recipient Immunity Transfer
Completed NCT02756572 - Early Allogeneic Hematopoietic Cell Transplantation in Treating Patients With Relapsed or Refractory High-Grade Myeloid Neoplasms Phase 2
Terminated NCT02877082 - Tacrolimus, Bortezomib, & Thymoglobulin in Preventing Low Toxicity GVHD in Donor Blood Stem Cell Transplant Patients Phase 2
Completed NCT02543879 - Study of a Novel BET Inhibitor FT-1101 in Patients With Relapsed or Refractory Hematologic Malignancies Phase 1
Completed NCT02262312 - Iron Overload and Transient Elastography in Patients With Myelodysplastic Syndrome Phase 0
Completed NCT02188290 - Transplant-Related Mortality in Patients Undergoing a Peripheral Blood Stem Cell Transplantation or an Umbilical Cord Blood Transplantation N/A
Recruiting NCT02330692 - Cohort Study of New Prognostic Factors With Peripheral Blood and Bone Marrow Evaluation at the Time of Diagnosis and Relapse in Myelodysplastic Syndrome
Completed NCT01684150 - A Phase 1, Open-Label, Dose-Escalation & Expanded Cohort, Continuous IV Infusion, Multi-center Study of the Safety, Tolerability,PK & PD of EPZ-5676 in Treatment Relapsed/Refractory Patients With Leukemias Involving Phase 1